News

Deck Bio and ReTrax Score Golden Tickets for Innovation Support

Deck Bio and ReTrax Score Golden Tickets for Innovation Support

Deck Bio and ReTrax Therapeutics Achieve Success

Winners receive $50,000 credit to LabCentral's flagship site.

LabCentral recently announced the exciting news that Deck Bio and ReTrax Therapeutics have been awarded prestigious LabCentral Golden Tickets by Bristol Myers Squibb (BMS). This recognition was celebrated on October 8, during a final evaluation round judged by prominent leaders from BMS.

What Do the Golden Tickets Offer?

The Golden Tickets represent a $50,000 credit towards space and services at LabCentral's flagship site, allowing the recipients to utilize these resources over the next 13 months. This initiative is focused on fields such as oncology, immunology, cardiovascular disease, and neuroscience — areas that align closely with BMS's interests.

Bristol Myers Squibb's Commitment to Startups

As a Platinum Sponsor of LabCentral, Bristol Myers Squibb demonstrates a strong commitment to supporting the startup ecosystem. By offering Golden Tickets, they enable early-stage entrepreneurs to advance their innovative work while reaching critical development milestones. "At Bristol Myers Squibb, we are dedicated to fueling innovation across our local life sciences communities," shared Emma Lees, the senior vice president of Oncology Research and head of the Cambridge site for BMS.

The Impact of the Golden Ticket Program

Emma Lees emphasized how their support for LabCentral's program empowers promising startups that are working to create transformative medicines for patients. This commitment not only boosts groundbreaking scientific advancements but also enhances the reputation of the region as a global biotech hub. "Our partnerships mean a lot, fostering a supportive environment where biotechnology can thrive," she added.

Maggie O'Toole, the CEO of LabCentral, echoed these sentiments, stating that providing access to the necessary resources is central to LabCentral’s mission. She expressed gratitude toward BMS for their direct support of residency, illustrating how such involvement builds a robust startup community.

Innovative Work by Deck Bio

Deck Bio is on a mission to create best-in-class TCR therapeutics, which offer superior developability and safety while ensuring a broad patient coverage. Their innovative approach targets highly expressed cancer-specific peptide-MHCs, allowing for multi-target recognition with a single drug. This leads to better response rates and helps to minimize drug resistance, setting a new standard in cancer treatments.

ReTraX Therapeutics' Groundbreaking Initiatives

ReTraX Therapeutics is making strides in the realm of gene therapy. They are developing a one-time AAV gene therapy designed to upregulate FAN1, an enzyme responsible for DNA repair that stabilizes pathogenic repeat expansions. This innovative therapy aims to offer a durable, disease-modifying treatment for Huntington's disease first and is set to expand to address myotonic dystrophy and other repeat expansion disorders.

About LabCentral

As a private, non-profit entity, LabCentral serves as an essential launchpad for promising life sciences and biotech startups. Spanning over 200,000 square feet in Kendall Square and at the Harvard University campus, LabCentral was founded in 2013. It provides fully permitted laboratory and office spaces, along with comprehensive programming and networking opportunities for life sciences entrepreneurs. Over eleven years, LabCentral has seen its residents raise more than $20 billion in funding while creating thousands of jobs.

Frequently Asked Questions

What is the LabCentral Golden Ticket program?

The LabCentral Golden Ticket program offers startups a substantial credit towards resources and space at LabCentral, aimed at nurturing innovation.

Who were the recipients of the Golden Tickets?

Deck Bio and ReTraX Therapeutics received the Golden Tickets, enabling them to further their innovative research and development.

What does the $50,000 credit cover?

The credit can be utilized for space and services at LabCentral's flagship site, supporting the startups in their development phases.

Why does Bristol Myers Squibb support LabCentral?

Bristol Myers Squibb aims to foster innovation in local life sciences communities, supporting early-stage companies to advance their groundbreaking work.

How has LabCentral impacted the biotech community?

LabCentral has provided essential resources that have fueled significant funding and job creation in the life sciences sector, enhancing the region's biotech landscape.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

BioVersys AlpE Data Offers a Measured TB Treatment Signal

Updated Category News Views 75

Tuberculosis drug development rarely hands anybody a clean victory lap, and BioVersys' latest readout is no exception. The completed 14-day Phase 2a ENABLE study gives alpibectir plus ethionamide, known as AlpE, a credible early clinical signal in newly diagnosed drug-sensitive pulmonary TB. That matters. It does not, however, settle the far larger question of whether...

Continue Reading
Africa Tech Awards Put Infrastructure Back in Focus

Updated Category News Views 97

Twelve trophies in Cape Town tell a more useful story than most glossy technology forecasts ever manage to. The Africa Tech Festival Awards 2026, announced on November 19 during the event's 29th annual gathering, cut across connectivity, telecoms, AI, cybersecurity, data centres, cloud, fintech, startups and enterprise transformation. That breadth matters. Africa's...

Continue Reading
NEWWAVE Turns 15 and Chases a Bigger Tech Partner Role

Updated Category News Views 48

Fifteen years is about when an outsourced engineering shop has to prove it can be more than extra hands on a keyboard. NEWWAVE’s new identity and “Trusted Technology Partner” positioning are an attempt to make that jump: from carrying out software work to helping clients decide what work ought to be done, then sticking around after launch. It is a sensible ambition,...

Continue Reading
Securitize Tests the IPO Clock With Anthropic Tokens

Updated Category News Views 93

Anthropic did not even get a full trading day to itself before the tokenization crowd arrived. Securitize says Anthropic stock became available through Securitize Stocks on Solana on the company’s first day as a public company, a loud little signal that the old IPO playbook is being prodded from the edges. For investors, this is not merely another crypto-flavored...

Continue Reading
Cirrus CEO Takes SIA Chair as Chip Policy Heats Up

Updated Category News Views 148

A trade-group gavel rarely moves a stock by itself, but this one lands in a noisy part of the chip cycle. On November 19, 2026, the Semiconductor Industry Association elected Cirrus Logic President and CEO John Forsyth as chair of its board. That is not a revenue announcement, not a factory groundbreaking, and certainly not a reason to start flinging confetti at...

Continue Reading
Huhtamaki Maps Its 2027 Reporting Dates for Investors

Updated Category News Views 78

A calendar release rarely makes the pulse race, but it tells shareholders when the curtain will actually go up. Huhtamäki Oyj has laid out its 2027 financial reporting timetable, and the useful part is its plainness: investors now know the handful of dates when management will have to put numbers, not broad ambitions, in front of the market. For a packaging company, that...

Continue Reading
Korla Kiln Gains Show How Cement Efficiency Is Won

Updated Category News Views 53

A cement kiln does not care about corporate slogans; it cares whether the flame holds, the bearings stay alive, and the feed keeps moving. That is why the work at Xinjiang Tianshan Cement's Tashidian branch in Korla deserves a closer look. This is not a glossy tale about a futuristic factory appearing overnight. It is an account of an old, unforgiving industrial process...

Continue Reading
FLX Opens a New Door to Pre-IPO Deal Flow for Advisors

Updated Category News Views 172

Private-market chatter has been leaking past the velvet rope for years, and advisors are sick of learning about it after a client already has a pitch deck in hand. FLX Networks is responding to that irritation by letting its eligible advisor and wealth-management members review select pre-IPO opportunities shared by other members. Announced November 19, 2026, the move is...

Continue Reading
Humana's Medicare Audit Shock Puts Disclosure in Focus

Updated Category News Views 134

Medicare Advantage just reminded Wall Street that reimbursement plumbing can wreck a perfectly calm-looking stock in a hurry. Humana shareholders watched that lesson land hard on November 18, when reports surfaced of a proposed federal CRUSH rule aimed at fraud, waste, and improper payments in the program. The reported response in NYSE:HUM was ugly: an early account put...

Continue Reading
Sailun’s COP31 Pitch Rests on Tire Tech and Hard Proof

Updated Category News Views 91

Antalya Put Tire Chemistry on a Very Public Stage Rubber tires rarely get a starring role at a climate summit, which is exactly why Sailun Group’s appearance at COP31 deserves a closer look. From November 9 through 20 in Antalya, Türkiye, Chairwoman Yanhua Liu used the United Nations climate gathering to lay out the company’s case: better tire technology can cut...

Continue Reading

Top 5 Most Recently Viewed Articles

Market Trends: The Effects of Inflation on Stock Futures

Updated Category News Views 87

Understanding Stock Market Movements Amid Inflation The stock market is always changing, and the way inflation data interacts with labor statistics often shapes its future direction. Recently, U.S. stock futures saw a slight uptick as investors digested fresh figures, weighing how these will influence upcoming decisions regarding interest rate cuts. Current Market...

Continue Reading
SMBC Nikko America Achieves Primary Dealer Status with Fed

Updated Category News Views 557

SMBC Nikko America Achieves Primary Dealer Designation SMBC Nikko Securities America, Inc., commonly referred to as SMBC Nikko America, has recently been honored with the designation of primary dealer by the Federal Reserve Bank of New York. This prestigious status is not only a recognition of the firm’s robust capabilities but also signals significant opportunities for...

Continue Reading
USD and Global Currency Trends Amid Upcoming Economic Events

Updated Category News Views 272

Currency Market Insights for the Upcoming Week As economic indicators and central bank policies loom large, the focus shifts to the financial markets where currencies react to evolving data. The US dollar has shown resilience recently, making a notable comeback. This rebound is attributed to a combination of safe haven flows and exceptionally positive data releases. Fed...

Continue Reading
Transforming $100 into Wealth: American Tower's Success Story

Updated Category News Views 152

The Wealth Generated by American Tower's Growth American Tower (NYSE: AMT) has exhibited exceptional performance over the past two decades, consistently outshining the market with a remarkable annual return of 10.05%. As of now, this powerhouse company boasts a market capitalization of approximately $83 billion, signaling its robust position in the telecommunications...

Continue Reading
Calcea: The Future of Calcium with Plant-Based Solutions

Updated Category News Views 258

Revolutionizing Calcium Supplements with Calcea Calcium is recognized as the most abundant mineral in the human body, yet many of the supplements available today are derived from ground-up rocks – materials that aren't aligned with the nutritional needs of the human body. With consumers increasingly prioritizing cleaner and more effective supplements, the calcium market...

Continue Reading